ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)

Clinical trial NCT06378138 · RECRUITING

Trial details

NCT number: NCT06378138
Sponsor: Beijing InnoCare Pharma Tech Co., Ltd.
Status: RECRUITING
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Hematologic Malignancies

Start date: 2024-05-15
Primary completion: 2030-11-25
Enrollment: 226

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.